1335 - Front-line treatment with docetaxel, cisplatin and bevacizumab for patients with advanced/metastatic non-small cell lung cancer: a multicenter phase...

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Cytotoxic agents
Non-small-cell lung cancer
Biological therapy
Presenter Nikolaos Kentepozidis
Authors N. Kentepozidis1, M. Agelidou1, C. Christophylakis1, A. Kotsakis2, N. Vardakis1, D. Stoltidis1, E. Kontopodis1, A. Xyrafas1, S. Agelaki1, V. Georgoulias1
  • 1Medical Oncology, Hellenic Oncology Research Group (HORG), 11470 - Athens/GR
  • 2Medical Oncology, Hellenic Oncology Research Group (HORG), 11474 - Athens/GR



To evaluate in a multicenter phase II study the efficacy and tolerance of the docetaxel/cispaltin combination in association with bevacizumab (DCV regimen) in metastatic nom-small cell lung cancer (NSCLC) patients.


48 chemotherapy-naïve patients with measurable, histologically confirmed, non-squamous, IIIB (wet)/IV NSCLC and PS 0-2 were eligible for treatment and received docetaxel (75mg/m2 IV), cisplatin (80 mg/m2 IV) and bevacizumab (15 mg/kg IV) in cycles of 21 days. Patients did not receive maintenance bevacizumab.


All patients were eligible for response. Complete and partial responses were achieved in two (4,2%) and 14 (29.2%) patients, respectively [overall response rate: 33,3%; 95% CI = (20.0%-46.7%)] whereas stable disease was documented in 14 patients. The median PFS was 4, 4 months (95% CI: 1,32-7,48) and the median OS 13,27 (95% CI: 9,72-16,81). Treatment-related grade 3 or 4 hematologic adverse events were leucopenia, neutropenia, and anemia in 8,4%, 18,7% and 2,1% of the patients, respectively. Three (6,3%) patients developed grade 2-4 febrile neutropenia and one (2.1%) patient (2,1%) died because of sepsis due to bowel perforation.


The DCV regimen is an active regimen with manageable toxicity when administered as front line treatment in patients with advanced non-squamous NSCLC and merits to be further investigated.


All authors have declared no conflicts of interest.